<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251978</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4927s</org_study_id>
    <nct_id>NCT01251978</nct_id>
  </id_info>
  <brief_title>Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)</brief_title>
  <official_title>Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Retina Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients
      with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help
      reduce the number of laser treatments that might be needed to control the tumor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Thickness</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity (LogMar)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>High dose Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 2 mg</intervention_name>
    <description>intravitreal injections of ranibizumab once a month, times 3.</description>
    <arm_group_label>High dose Ranibizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg Ranibizumab</intervention_name>
    <description>6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
    <arm_group_label>Standard Dose Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Primary pigmented or amelanotic choroidal melanoma measuring 16 mm or less in the
             largest basal diameter and 6 mm or less in the apical height.

          -  Location of the tumor, posterior to the equator of the eye.

          -  Documented growth of tumor by A-B scan.

          -  Ability to provide written informed consent and comply with the study assessment for
             the full duration of the study.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Premenopausal women not using adequate contraception.

          -  Current infection or inflammation in either eye.

          -  Extension of tumor into the orbit.

          -  Regional spread or metastatic disease.

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

          -  Any known allergy to any of the components to be used in the study.

          -  Participation in another simultaneous medical investigation or trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter E Liggett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Retina Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.retinamd.com</url>
    <description>New England Retina Associates website. It contains all the clinical trials that we are running.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>October 17, 2016</results_first_submitted>
  <results_first_submitted_qc>October 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal melanoma</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Transpupillary Thermotherapy</keyword>
  <keyword>CSTIP</keyword>
  <keyword>Indocyanine Green</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>10 participants were enrolled - 2 participants were eliminated early in the study for non compliance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Ranibizumab</title>
          <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose Ranibizumab</title>
          <description>patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Ranibizumab</title>
          <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
        </group>
        <group group_id="B2">
          <title>Standard Dose Ranibizumab</title>
          <description>patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications.</title>
        <time_frame>1 year</time_frame>
        <population>complications were only assessed in the high dose group</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ranibizumab</title>
            <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications.</title>
          <population>complications were only assessed in the high dose group</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vascular occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>retinal detachment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>persistent sub retinal fluid (srf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>metastatic death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Thickness</title>
        <time_frame>baseline and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ranibizumab</title>
            <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Ranibizumab</title>
            <description>patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Thickness</title>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" lower_limit="2.5" upper_limit="7.48"/>
                    <measurement group_id="O2" value="2.91" lower_limit="2.5" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68">no measure of dispersion is available - PI left and there is no data available</measurement>
                    <measurement group_id="O2" value="0.79">no measure of dispersion is available - PI left and there is no data available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity (LogMar)</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ranibizumab</title>
            <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Ranibizumab</title>
            <description>patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity (LogMar)</title>
          <units>LogMar</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient 01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not applicable for this arm</measurement>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 02</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not applicable for this arm</measurement>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 03</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not applicable for this arm</measurement>
                    <measurement group_id="O2" value="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 04</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="NA">not applicable for this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 05</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="NA">not applicable for this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 06</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="NA">not applicable for this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 07</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">not applicable for this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="NA">not applicable for this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse event data are not available to be reported per group or according to severity because the PI left the institution and adverse event data in the required format is not available.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose Ranibizumab</title>
          <description>patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose Ranibizumab</title>
          <description>patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Hurst- study coordinator</name_or_title>
      <organization>New England Retina Associates</organization>
      <phone>203-288-2020</phone>
      <email>lhurst@retinamd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

